Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
September 16, 2021 08:00 ET
|
Ayala Pharmaceuticals
- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease...
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 02, 2021 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
September 01, 2021 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 08:00 ET
|
Ayala Pharmaceuticals
- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors - Multiple Near-Term Milestones Across Clinical-Stage Pipeline - Updated ACCURACY Trial...
Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
July 06, 2021 09:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing...
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
May 27, 2021 09:01 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 08:15 ET
|
Ayala Pharmaceuticals
- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis’ Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the...
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
April 21, 2021 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
March 25, 2021 08:00 ET
|
Ayala Pharmaceuticals
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On...
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
March 02, 2021 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...